Upstream processing of plasmid DNA for vaccine and gene therapy applications

Recent Patents on Biotechnology

Volumn 2, Issue 3, 2008, Pages 156-172

  Tejeda Mansir, Armando ^a   Montesinos, Rosa M ^a  

^a UNIVERSIDAD DE SONORA   (Mexico)

Author keywords

Growth media; Plasmid DNA; Plasmid DNA fermentation; Plasmid DNA host strain; Production of plasmid DNA

Indexed keywords

BIOMOLECULES; ESCHERICHIA COLI; FERMENTATION; GENE EXPRESSION; GENE THERAPY; NUCLEIC ACIDS; PATENTS AND INVENTIONS;

GROWTH MEDIUM; HOST STRAIN; HUMAN CELLS; PLASMID DNA; PLASMID DNA FERMENTATION; PLASMID DNA HOST STRAIN; PRODUCTION OF PLASMID DNA;

VACCINES;

CARBON; CELL RECEPTOR; DISSOLVED OXYGEN; DNA VACCINE; MINERAL; NITROGEN; NUCLEIC ACID; PLASMID DNA; PLASMID VECTOR; SODIUM CHLORIDE; VIRUS VECTOR;

BATCH FERMENTATION; BIOMASS PRODUCTION; CARBON SOURCE; CELL LYSATE; CLINICAL TRIAL; CONTINUOUS FERMENTATION; DNA FLANKING REGION; DNA IMMUNIZATION; DRUG DESIGN; DRUG EFFICACY; DRUG MANUFACTURE; DRUG STABILITY; ESCHERICHIA COLI; EUKARYOTE; FED BATCH FERMENTATION; FERMENTATION MEDIUM; FERMENTATION OPTIMIZATION; FERMENTATION TECHNIQUE; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSFECTION; GROWTH RATE; HOST SELECTION; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION; INOCULATION; INTRON; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PATENT; PH; PRIORITY JOURNAL; PROCESS DESIGN; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PRODUCTIVITY; PROMOTER REGION; QUALITY CONTROL; RELIABILITY; REVIEW; SAFETY; SEQUENCE ANALYSIS; TEMPERATURE SENSITIVITY; TRANSCRIPTION TERMINATION;

EID: 58149122980     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/187220808786241015     Document Type: Review

References (115)

1. Duarte S, Fortes A, Prazeres D, Marcos J. Preparation of plasmid DNA polyplexes from alkaline lysates by a two-step aqueous two-phase extraction process. J Chromatogr A 2007; 1164(1-2): 105-112.
2. Zhang Q, Bi J, Xiao F, Duan H, Wu B, Wu Z. Production of plasmid DNA encoding human hepatocyte growth factor for gene therapy. Biotechnol Appl Biochem 2008; 49: 11-16.
3. Manthorpe M, Hobart P, Ferrari M, Geall A, Goff B, Rolland A. Plasmid vaccines and therapeutics: from design to applications. Adv Biochem Engin/Biotechnol 2005; 99: 41-92.
4. Rolland A, Sullivan SM. Pharmaceutical gene delivery systems. Marcel Dekker, Cold Spring Harbor, NY, 2003.
5. Edelstein M, Abedi M, Wixon J. Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 2007; 9(10): 833-842.
6. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
7. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-354.
8. Glenting J, Wessels S. Ensuring safety of DNA vaccines. Microbial Cell Factories 2005; 4: 26.
9. Liu MA, Hedestam, WB. DNA vaccines: Recent developments and future possibilities. Hum Gene Ther 2006; 17: 1051-1061.
10. Listner K, Bentley L, Okonkowski J, Kistler C, Wnek R, Caparoni A, Junker B, Robinson D, Salmon P, Chartrain M. Development of a highly productive and scalable plasmid DNA production platform. Biotechnol Prog 2006; 22: 1335-1345.
11. Prather KJ, Sagar S, Murphy J, Chartrain M. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Microb Technol 2003; 33: 865-883.
12. Prazeres DMF, Monteiro GA, Ferreira GNM, Diogo MM, Ribeiro SC, Cabral JMS. Purification of plasmids for gene therapy and DNA vaccination. In: Biotechnology Annual Review. Ed.: El-Gewely, MR. Elsevier. Amsterdam. 2001; 7: 1-30.
13. Okonkowski J, Kizer-Bentley L, Listner K, Robinson D, Chartrain M. Development of a robust, versatile, and scalable inoculum train for the production of a DNA vaccine. Biotechnol Prog. 2005; 21(4): 1038-1047.
14. Chartrain, M., Bentley, L.K., Krulewicz, B.A., Listner, K.M., Sun, W., Lee, C. B.: WO05078115 (2005).
15. Dhama K, Mahendran M, Gupta P, Rai A. DNA vaccines and their applications in veterinary practice: current perspectives. Vet Res Comun 2008; 32(5): 341-356.
16. Prazeres D, Ferreira G, Monteiro G, Cooney C, Cabral J. Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks. TIBTECH 1999; 17(4): 169-174.
17. Carnes, A. Fermentation design for the manufacture of therapeutic plasmid DNA. BioProcess Int. 2005; 36-44.
18. Rozkov A, Avignone-Rossa C, Ertl P, Jones P, O'Kennedy R, Smith J, et al. Fed batch culture with declining specific growth rate for high-yielding production of a plasmid containing a gene therapy sequence in Escherichia coli DH1. Enzyme Microb Technol 2006; 39(1): 47-50.
19. 3 fermentation scale for an influenza pandemic. Biotechnol Progr 2005; 21(6): 1577-1592.
20. Prazeres, D.M.F., Diogo, M.M., De Sampaio, Queiroz J. A.: US20077169917 (2007).
21. Carnes A, Hodgson C, Williams J. Inducible Escherichia coli fermentation for increased plasmid DNA production. Biotechnol Appl Biochem 2006; 45: 155-166.
22. Freitas S, Santos J, Prazeres D. Optimization of isopropanol and ammonium sulfate precipitation steps in the purification of plasmid DNA. Biotechnol Progr 2006; 22(4): 1179-1186.
23. Zhang, Q, Bi J, Xiao F, Duan H, Wu B, Wu Z. Production of plasmid DNA encoding human hepatocyte growth factor for gene therapy. Biotechnol Appl Biochem 2008; 49: 11-16.
24. Rozkov A, Larsson B, Gillstrom S, Bjornestedt R, Schmidt S. Large-scale production of endotoxin-free plasmids for transient expression in mammalian cell culture. Biotech Bioeng 2008; 99(3): 557-566.
25. Peterson M, Brune B. Maximizing yields of plasmid DNA processes - High cell density processes can produce high yields without compromising quality. Biopharm International 2008; 16.
26. O'Kennedy R, Ward J, Keshavarz-Moore E. Effects of fermentation strategy on the characteristics of plasmid DNA production. Biotechnol Appl Biochem 2003; 37: 83-90.
27. Vologodskii AV, Cozzarelli NR. Conformational and thermodynamic properties of supercoiled DNA. Annu Rev Biophys Biomol Struct 1994; 23: 609-643.
28. Prazeres D. Prediction of diffusion coefficients of plasmids. Biotech Bioeng 2008; 99(4): 1040-1044.
29. Smith C, DePrince R, Dackor J, Weigl D, Griffith J, Persmark M. Separation of topological forms of plasmid DNA by anion-exchange HPLC: Shifts in elution order of linear DNA. J Chromatogr B 2007; 854(1-2): 121-127.
30. Vázquez R, Brito JE, Pérez M, Silva R, Seralena A, Dueñas-Carrera S, Frontela MC, Herrera AM.. Plasmid DNA production for gene therapy and therapeutic or preventive vaccination in humans: a challenge for the pharmaceutical industry. Biotecnología Aplicada 2005; 22(4): 251-255.
31. Huber, H., Weigl, G., Buchingr, W.: WO05097990 (2005).
32. Montgomery DL, Prather KJ. Design of plasmid DNA constructs for vaccines. DNA Vaccines. In: Methods and Protocols. Eds.: Saltzman, W. Mark; Shen, Hong; Brandsma, Janet L. 2nd edition. Series: Methods in Molecular Medicine. Humana Press 2006; 127, 11-22.
33. Law J, Buist G, Haandrikman A, Kok J, Venema G, Leenhouts K. A system to generate chromosomal mutations in lactococcus-lactis which allows fast analysis of targeted genes. J Bacteriol 1995; 177(24): 7011-7018.
34. European Medicines Agency: Report from the ad hoc meeting of CPMP Gene Therapy Expert Group. 23-24 January 2003. EMEA-5382-03- Final.
35. Gallot D, Seifer I, Lemery D, Bignon YJ. Systemic diffusion including germ cells after plasmidic in utero gene transfer in the rat. Fetal Diagn Ther 2002; 17: 157-162.
36. William, J.A.: WO06081529 (2006).
37. Twigg A, Sherratt D. Transc-complementable copy-umber mutants of plasmid Cole1. Nature 1980; 283(5743): 216-218.
38. Lin-Chao S, Chen W, Wong TT. High copy number of the pUC plasmid results from a Rom/Rop-suppressible point mutation in RNA II. Mol Microbiol 1992; 6: 3385-3393.
39. Lahijani R, Hulley G, Soriano G, Horn NA, Marquet M. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther. 1996; 7: 1971-1980.
40. Wong E, Muesing M, Polisky B. Temperature-sensitive copy number mutants of cole1 are located in an untranslated region of the plasmid genome. Proc. Natl. Acad. Sci. USA. 1982; 79(11): 3570-3574.
41. Remaut E, Tsao H, Fiers W. Improved plasmid vectors with a thermoinducible expression and temperature-regulated runaway replication. Gene 1983; 22, 103 -113.
42. USFDA (Ed.). Guidance for Industry. Considerations for plasmid DNA vaccines for infectious disease indications. US FDA Center for Biologics Evaluation and Research, Rockville, MD, USA, 2007.
43. Guidance for Industry #159. Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish a microbiological ADI VICH GL-36. 2006.
44. Morsey, M.A.: US5922583 (1999).
45. Khaan, M.A., McNeil, H.V., Hormaeche, C.E.: WO9740169 (1997).
46. Lew D, Parker S, Latimer T, Abai A, Kuwahararundell A, Doh S, et al. Cancer gene-therapy using plasmid DNA - Pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995; 6(5): 553-564.
47. Punnonen, J., Wright, A., Semyonou, A.: US20067074590 (2006).
48. Wright A, Semyonov A, Dawes G, Crameri A, Lyons R, Stemmer W, et al. Diverse plasmid DNA vectors by directed molecular evolution of cytomegalovirus promoters. Hum Gene Ther 2005; 16(7): 881-892.
49. National Center for Infectious Diseases. http://www.cdc.gov/cmv/
50. Cheng L, Ziegelhoffer PR, Yang NS. in vivo. Promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993; 90: 4455-4459.
51. Le Hir H, Nott A, Moore M. How introns influence and enhance eukaryotic gene expression. Trends Biochem Science 2003; 28(4): 215-220.
52. Sung, Y. C., Yang, S., Im, S., Lee, C., Park, S., Song, M., Son, J., Kim, C., Kim, B., Lee, S., Kim, W.: WO08020656 (2008).
53. Jiang C, Magee DM, Ivey FD, Cox RA: Role of signal sequence in vaccine-induced protection against experimental coccidioidomycosis. Infect Immun 2002; 70: 3539-3545.
54. Barash S, Wang W, Shi Y. Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression. Biochem Biophys Res Commun 2002; 294: 835-842.
55. Saha, D.P.: WO05047512 (2005).
56. Wu, C., Tao, M.: US20070190617 (2007).
57. Helen S Garmory, Katherine A Brown and Richard W Titball. DNA vaccines: improving expression of antigens. Genetic Vaccines and Therapy 2003, 1: 2.
58. Williams, W.V., Madaio, M., Weiner, D. B.: US20016228621 (2001).
59. Gerloni, M.: WO08017568 (2008).
60. Austin, S.J.: WO0028049 (2000).
61. Shin H, Lim H. Optimal fed-batch operation for recombinant cells with segregational plasmid instability. Chem Eng Commun 2008; 195(9): 1122-1143.
62. Kohama, K., Kobayashi, M., Kurusu, Y., Yukawa, H., Fukushima, M.: US5185262 (1993).
63. McKay, L.L., Polzin, K.M.: US5459072 (1995).
64. Sherratt, D. J., Williams, S.G, Hanak, J. A. J.: WO97/09435 (1997).
65. Vaughn, S.: US080057545 (2008).
66. Reed, T.D., Zhou, J.F.: US20080050808 (02008).
67. Levy, J.: US20087390654 (2008).
68. Blattner, F.R., Campbell, J.W., Plunkett, G.: WO07140274 (2007).
69. Bagosian, G., O'Neil, J.P., Smith, H.Q.: WO070353323 (2007).
70. Galen, J.E.: US20067125720 (2006).
71. Williams, J.A.: WO06081529 (2006).
72. Draghia-Akli, R., Abruzzese, R., Kern, D.R.: WO04007678 (2004).
73. Huber, H., Pacher, C., Necina, R., Kollmann, F., Reinisch, C.: WO05098002 (2005).
74. Kuhnert P, Nicolet J, Frey J. Rapid and accurate identification of Escherichia coli k-12 strains. Appl Environm Microbiol 1995; 61(11): 4135-4139.
75. Williams, J.A., Hodgson, C.P.: US20070249042 (2007).
76. Gowrishaankar, J., Harinarayanan, R.: US20077176028 (2007).
77. Hodgson, C.P., Williams, J.A.: WO06026125 (2006).
78. Blattner, F.R., Posfai, G., Herring, C.D., Plunkett, G., Glasner, J.D.: US20066989265 (2006).
79. Blattner, F.R.: US20060199257 (2006).
80. Grabherr, R., Pfaffenzeller, I.: WO06029985 (2006).
81. Curtiss, R.: US20056872547 (2005).
82. Chen W, Graham C, Ciccarelli RB. Automated fed-batch fermentation with feed-back controls based on dissolved oxygen (DO) and pH for production of DNA vaccines. J. Ind Microbiol Biotech 1997; 18: 43-49.
83. Olson, T., Marquet, M. and Horn, N.: US9609746 (1996).
84. Thatcher, D. R., Hitchcock, A. G., Hanak, J. A., Varley, D. L.: WO9729190 (1997).
85. Carnes, A.E.: WO07089873 (2007).
86. Hamann, C.W., Nielsen J., Ingerslev, E.: WO0028048 (2000).
87. Voss, C.: WO02064752 (2002).
88. O'Kennedy R, Baldwin C, Keshavarz-Moore E. Effects of growth medium selection on plasmid DNA production and initial processing steps. J Biotechnol 2000; 76: 1751-83.
89. Wan, N.C., Goodrick, J.C.: US005487986 (1996).
90. Schmidt, T., Friehs, K., Flaschel, E., Schleef, M.: US20036664078 (2003).
91. Xu Z, Shen W, Chen H, Cen P. Effects of medium composition on the production of plasmid DNA vector potentially for human gene therapy. J Zhejiang University Science 2005; 6B(5): 396-400.
92. Danquah MK, Forde GM. Growth medium selection and its economic impact on plasmid DNA production. J biosc bioeng. 2007; 104(6): 490-497.
93. Tholudur A, Sorensen T, Zhu X, Shepard S. Using design of experiments to assess Escherichia coli fermentation robustness. BioProcess International October 2005.
94. Shi F, Xu Z, Cen P. Optimization of gamma-polyglutamic acid production by Bacillus subtilis ZJU-7 using a surface-response methodology. Biotechnol Bioprocess Eng 2006; 11(3): 251-257.
95. Nikerela IE, Önerb ET, Kirdara B, Yildirim R. Optimization of medium composition for biomass production of recombinant Escherichia coli cells using response surface methodology. Biochem Eng J 2006; 32(1): 1-6.
96. Niccolai A, Fontani S, Kapat A, Olivieri R. Maximization of recombinant Helicobacter pylori neutrophil activating protein production in Escherichia coli: improvement of a chemically defined medium using response surface methodology. FEMS Microbiol Lett 2003; 221(2): 257-262.
97. Zheng S, Friehsz K, He N, Deng X, Li Q, He Z, et al. Optimization of medium components for plasmid production by recombinant E coli DH5 alpha pUK21CMV beta 1.2. Biotechnol Bioprocess 2007; 12(3): 213-221.
98. Carnes AE, Williams JA. Plasmid DNA manufacturing technology. Recent Patents on Biotechnology 2007; 1: 151-166.
99. Carnes, A.E., Williams, J.A.: WO06023546 (2006).
100. O'Mahony K, Freitag R, Hilbrig F, Schumacher I, Muller P. Integration of bacteria capture via filtration and in situ lysis for recovery of plasmid DNA under industry-compatible conditions. Biotechnol Prog 2007; 23(4): 895-903.
101. Silva F, Passarinha L, Sousa F, Queiroz J, Domingues F. Preliminary studies on medium and fermentation strategy design for plasmid DNA production. J Biotechnol 2007; 131(2): S166-S167.
102. Passarinha L, Diogo M, Queiroz J, Monteiro G, Fonseca L, Prazeres D. Production of ColE1 type plasmid by Escherichia coli DH5 alpha cultured under nonselective conditions. J Microbiol Biotechnol 2006; 16(1): 20-24.
103. Chen, Y., Kendirgi, F.: WO06063355 (2006).
104. Kelly WJ. Perspectives on plasmid-based gene therapy: challenges for the product and the process. Biotechnol Appl Biochem 2003; 37: 219-223.
105. PDA. Fundamentals of an environmental monitoring program. PDA J. Pharm Sci Technol 2001; 55: 1-35.
106. Duttweiler, H.M., Gross, D.S.: US20016255099 (2001).
107. Thatcher, D. R., Hitchcock, A., Hanak, J. A. J., Varley, D.: US20036503738 (2003).
108. Chen, W.: US5955323 (1999).
109. Yakhchali B, Karami A, Aflaki E, Ahmadi A. Plasmid DNA production for genetic immunization in fed-batch fermentation with feed back controls based on dissolved oxygen (DO) and pH. J. Sciences 2007; 18(2): 129-133.
110. Schuler, M.L., Katgi, F. Bioprocess Engineering. Basic concepts. 2ed edition. Printice Hall PTR. Upper Saddle Rives, NJ.
111. Malhotra G. Drug Discovery and Development Magazine 2007; 10(6): 30-31.
112. EMEA (Ed.), Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products. The European Agency for the Evaluation of Medicinal Products, 2005.
113. Prazeres D, Ferreira G. Design of flowsheets for the recovery and purification of plasmids for gene therapy and DNA vaccination. Chem Eng Proc 2004; 43(5): 609-24.
114. Urthaler J, Buchinger W, Necina R. Improved downstream process for the production of plasmid DNA for gene therapy. Acta Biochimica Polonica 2005; 52(3): 703-711.
115. FDA (Ed.) Points to consider in the characterization of cell lines used to produce biologics, Food and Drug Administration, Rockville MD, USA, 1993.